Equities

Ginwa Enterprise Group Inc

600080:SHH

Ginwa Enterprise Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.78
  • Today's Change-0.11 / -1.60%
  • Shares traded4.76m
  • 1 Year change-11.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ginwa Enterprise Group Inc is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company operates its businesses through three segments. The Pharmaceutical Industry segment is mainly engaged in the production of pharmaceuticals. The Company's products are divided into four series, including orthopedics, immunology, children's and general medicines, mainly covering chemicals, Chinese patent medicines, active pharmaceutical ingredient and health care products. The Hotel Industry segment is mainly engaged in the operation of hotels. The Pharmaceutical Commercial segment is mainly engaged in the sales of pharmaceuticals. The Company mainly operates its businesses in the domestic market.

  • Revenue in CNY (TTM)581.53m
  • Net income in CNY-15.51m
  • Incorporated1996
  • Employees553.00
  • Location
    Ginwa Enterprise Group IncNo. 202 Science 4th Road, Hi-tech ZoneXI'AN 710075ChinaCHN
  • Phone+86 2 988336635
  • Fax+86 2 981778626
  • Websitehttp://www.ginwa.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hanshang Group Co Ltd1.28bn-5.18m2.39bn2.38k--1.40--1.87-0.016-0.0164.315.800.3622.528.04536,620.30-0.44512.00-0.75013.8953.6057.24-1.234.890.26881.180.316315.030.18935.14-32.2425.6212.88--
Ginwa Enterprise Group Inc581.53m-15.51m2.57bn553.00--1.69--4.42-0.0382-0.03821.584.070.29684.815.281,051,591.00-0.79160.3641-0.95150.414176.1873.64-2.671.152.190.1960.0431124.25-2.41-5.37-228.19--61.66--
Novoprotein Scientific Inc134.56m-21.29m2.65bn579.00--1.24--19.73-0.3031-0.30311.9230.570.05920.58331.96232,406.80-0.937---0.959--61.17---15.82--34.60--0.0323---42.09---85.84------
Zhejiang Cheng Yi Pharmaceutical Co Ltd732.68m166.02m2.72bn738.0016.402.19--3.720.50720.50722.243.800.40132.0117.68992,793.709.0712.0111.1714.7566.1369.7922.6022.841.01--0.199836.442.544.240.812910.94-23.5612.84
Data as of Nov 14 2024. Currency figures normalised to Ginwa Enterprise Group Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.09%Per cent of shares held by top holders
HolderShares% Held
Baoying Fund Management Co., Ltd.as of 30 Jun 2024165.00k0.05%
China Southern Asset Management Co., Ltd.as of 30 Jun 202456.00k0.02%
Sealand Securities Co., Ltd. (Investment Management)as of 30 Jun 202433.20k0.01%
China Asset Management Co., Ltd.as of 30 Jun 202425.10k0.01%
Peng Yang Amc Fund Management Co. Ltd.as of 30 Jun 2024100.000.00%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20240.000.00%
Guotai Asset Management Co., Ltd.as of 30 Jun 20240.000.00%
Western Leadbank Fund Management Co., Ltdas of 30 Jun 20240.000.00%
Tebon Fund Management Co. Ltd.as of 30 Jun 20240.000.00%
Gfund Management Co., Ltd.as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.